Zai Lab (NASDAQ:ZLAB) Insider Joshua L. Smiley Acquires 10,000 Shares

Key Points

• Insider Purchase: Zai Lab insider Joshua Smiley bought 10,000 shares for $289,100, increasing his ownership by 13.05% to a total of 86,604 shares.
• Recent Stock Performance: Zai Lab's stock traded at $32.80, with a market cap of $3.67 billion and a price-to-earnings ratio of -16.08, indicating volatility and investors’ mixed sentiments.
• Analyst Ratings: Brokerages have a consensus rating of "Moderate Buy" for Zai Lab, with several analysts setting target prices ranging from $52.00 to $75.00.

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) insider Joshua L. Smiley bought 10,000 shares of the firm's stock in a transaction on Wednesday, September 10th. The stock was bought at an average price of $28.91 per share, with a total value of $289,100.00. Following the completion of the purchase, the insider owned 86,604 shares of the company's stock, valued at $2,503,721.64. This trade represents a 13.05% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Zai Lab Price Performance

Shares of NASDAQ ZLAB traded up $0.28 during mid-day trading on Wednesday, hitting $32.58. The company had a trading volume of 306,069 shares, compared to its average volume of 812,990. Zai Lab Limited Unsponsored ADR has a 12 month low of $20.17 and a 12 month high of $44.34. The stock has a market cap of $3.64 billion, a price-to-earnings ratio of -15.97 and a beta of 1.04. The firm's 50 day simple moving average is $34.60 and its two-hundred day simple moving average is $33.96.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.37) EPS for the quarter, hitting analysts' consensus estimates of ($0.37). The firm had revenue of $109.98 million during the quarter, compared to the consensus estimate of $125.66 million. Zai Lab had a negative return on equity of 27.32% and a negative net margin of 49.68%. Zai Lab has set its FY 2025 guidance at EPS. Equities analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.

Institutional Investors Weigh In On Zai Lab

A number of large investors have recently made changes to their positions in ZLAB. Kingsview Wealth Management LLC grew its holdings in shares of Zai Lab by 6.0% in the 1st quarter. Kingsview Wealth Management LLC now owns 9,323 shares of the company's stock worth $337,000 after purchasing an additional 529 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in Zai Lab during the fourth quarter worth about $29,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Zai Lab by 2.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,114 shares of the company's stock worth $1,496,000 after buying an additional 1,200 shares in the last quarter. Walleye Capital LLC raised its stake in shares of Zai Lab by 6.4% in the first quarter. Walleye Capital LLC now owns 22,276 shares of the company's stock valued at $805,000 after acquiring an additional 1,338 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in Zai Lab by 13.4% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 12,544 shares of the company's stock worth $453,000 after acquiring an additional 1,483 shares during the last quarter. Institutional investors and hedge funds own 41.65% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Citigroup reiterated a "buy" rating and set a $69.00 price target (up previously from $66.00) on shares of Zai Lab in a research report on Monday, August 11th. Wall Street Zen downgraded shares of Zai Lab from a "buy" rating to a "hold" rating in a research report on Friday, June 27th. Leerink Partners set a $75.00 price objective on shares of Zai Lab and gave the company an "outperform" rating in a report on Monday, June 30th. Finally, Jefferies Financial Group initiated coverage on shares of Zai Lab in a research note on Monday, August 25th. They set a "buy" rating and a $52.00 price objective on the stock. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Zai Lab currently has an average rating of "Moderate Buy" and an average price target of $56.35.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.